Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Mayo Clinic proceedings

• Publication date

  2006-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4065/81.2.159PMID 16471068
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Myeloproliferative Disorders and Myelodysplastic Syndromes

  2007cited by this paper
• The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

  2005cited by this paper
• Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera.

  2005cited by this paper
• Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.

  2005cited by this paper
• Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

  2005cited by this paper
• Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study.

  2005cited by this paper
• White blood cell count and the incidence of ischemic stroke in coronary heart disease patients.

  2005cited by this paper
• FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia.

  2004cited by this paper
• Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.

  2004cited by this paper
• Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman

  2004cited by this paper
• Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

  2004cited by this paper
• Leukocyte Count as an Independent Predictor of Recurrent Ischemic Events

  2004cited by this paper
• Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia.

  2003cited by this paper
• Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients

  2002cited by this paper
• A long-term retrospective study of young women with essential thrombocythemia.

  2001cited by this paper
• Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.

  2001cited by this paper
• The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia

  2001cited by this paper
• Increased circulating platelet–leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count

  2001cited by this paper
• Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area

  2000cited by this paper
• Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.

  2000cited by this paper
• Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment

  2000cited by this paper
• Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients

  1999cited by this paper
• Population‐based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976–1995

  1999cited by this paper
• Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia

  1999cited by this paper
• Should a platelet limit of 600 × 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages

  1998cited by this paper
• Age and sex distributions of hematological malignancies in the U.K.

  1997cited by this paper
• Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

  1995cited by this paper
• White blood cell count and cardiovascular disease. Insights from the Framingham Study.

  1992cited by this paper
• Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients

  1991cited by this paper
• Life expectancy of patients with chronic nonleukemic myeloproliferative disorders

  1991cited by this paper
• Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.

  1990cited by this paper
• The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy.

  1989cited by this paper

• Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study.

  2026cites this paper
• A Case of Essential Thrombocythemia Treated for Epileptic Peri-Ictal Psychiatric Symptoms Resulting in Appropriate Palliative Care

  2025cites this paper
• Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial

  2024cites this paper
• Essential thrombocytosis transformed AML with TP53 mutations and its clinical implications

  2024cites this paper
• Cerebral Sinus Vein Thrombosis and Gender: A Not Entirely Casual Relationship

  2023influential citation
• Application of Fourier Transform InfraRed spectroscopy of machine learning with Support Vector Machine and principal components analysis to detect biochemical changes in dried serum of patients with primary myelofibrosis.

  2023cites this paper
• Trombocitemia esencial

  2023cites this paper
• Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management.

  2022cites this paper
• Triple-negative Thrombocythemia and Subsequent Acute Lymphoblastic Leukemia with Additional Somatic Mutations

  2022cites this paper
• Analysis of factors associated with the development of myelofibrosis in polycythemia vera and essential thrombocythemia patients: a single-center experience

  2022cites this paper
• Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions

  2022cites this paper
• Essential Thrombocythemia: One-Center Data in a Changing Disease

  2022cites this paper
• Correlation of Thrombosis and Clinicohematological Parameters with JAK2V617F Mutation in Philadelphia-Negative CMPNs: A Study from India

  2022cites this paper
• Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

  2022influential citation
• Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm

  2022cites this paper
• Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms

  2022cites this paper
• Leukocytosis and MPNs: Where do we stand?

  2022cites this paper
• Essential Thrombocytosis in Patients <40 Years Old With Acute Coronary Syndromes: A Not So Uncommon Underlying Diagnosis Often Overlooked

  2022cites this paper
• Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study

  2022cites this paper
• Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia

  2022cites this paper
• Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer

  2022cites this paper
• Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension

  2021cites this paper
• Ischemic Stroke in a Young Man: Unraveling the Domain of Myeloproliferative Disorders

  2021cites this paper
• PEAR1 Genetic Variants in Essential Thrombocythemia: A New Study of The Prevalence and Association of PEAR1 Variants with Hematological Parameters and ET Mutations

  2021cites this paper
• Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

  2021cites this paper
• Late excess mortality in essential thrombocythemia: a population-based study in the Netherlands, 2001–2018

  2021cites this paper
• Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

  2021cites this paper
• Total Platelet Transcriptomics and Its Network Analysis by RNA-Seq and miRNA-Seq and PCA Application in Essential Thrombocythaemia

  2020cites this paper
• Esansiyel trombositoz ve polisitemi vera hastalarında depresyon ve anksiyete düzeyleri ile yaşam kalitesi arasındaki ilişki

  2020cites this paper
• Hemorrhage in Essential Thrombocythemia or Polycythemia Vera: Epidemiology, Location, Risk Factors, and Lessons Learned from the Literature

  2020cites this paper
• Triple-Negative Essential Thrombocythemia Complicated by Thrombosis and Acquired von Willebrand Disease in a Young Man

  2020cites this paper
• Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map.

  2020cites this paper
• Miyeloproliferatif Neoplazilerde JAK2V617F Mutasyonunun Endotel Hücresine Etkisi ve SOCS1-4 Gen Anlatımlarına Yansıması

  2020cites this paper
• Essential thrombocythemia: a hemostatic view of thrombogenic risk factors and prognosis

  2020cites this paper
• From Driver Mutations to Genomic Classification: Current & Future Perspectives on Myeloproliferative Neoplasms

  2020cites this paper
• Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia

  2020cites this paper
• The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep

  2020cites this paper
• Inhibitors of the blood coagulation process in patients with essential thrombocythemia.

  2020cites this paper
• Essential Thrombocythemia

  2020cites this paper
• GATA-1 a potential novel biomarker for the differentiation of essential thrombocythaemia and myelofibrosis a potential novel for the differentiation of essential

  2019cites this paper
• [Clinical features and diagnosis of Ph - negative myeloproliferative neoplasms occurring in conjunction with the antiphospholipid syndrome].

  2019cites this paper
• [Brain MRI-findings in Ph - negative myeloproliferative disorders].

  2019cites this paper
• Jak2v617f Mutation in Patients With Myeloproliferative Diseases And Those With Ischemic Heart Disease With Normal Coronary Angiography

  2019cites this paper
• The PVSG/WHO versus the Rotterdam European clinical, molecular and pathological diagnostic criteria for the classification of myeloproliferative disorders and myeloproliferative neoplasms (MPD/MPN): From Dameshek to Georgii, Vainchenker and Michiels 1950-2018

  2019cites this paper
• Essential thrombocythemia: Biology, clinical features, thrombotic risk, therapeutic options and outcome

  2019cites this paper
• Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular

  2019cites this paper
• Developments in diagnosis and treatment of essential thrombocythemia

  2019cites this paper
• GATA‐1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis

  2019cites this paper
• Therapeutic Apheresis—Applications for Hemorrhagic and Thrombotic Disorders

  2019cites this paper
• What cardiologists should know about essential thrombocythemia and acute myocardial infarction: report of two cases and advanced heart failure therapies considerations

  2019cites this paper
• Cerebrovascular Disorders Associated with Ph-Negative Myeloproliferative Diseases

  2019cites this paper
• Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.

  2019influential citation
• A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms

  2019cites this paper
• Thrombocytosis

  2019cites this paper
• The Relationship Between the JAK2-V617F Mutation Status and Predictors of Clinical Outcomes in Patients with Essential Thrombocythemia

  2019cites this paper
• Ischemia-Modified Albumin Levels in Essential Thrombocytosis

  2018cites this paper
• Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia

  2018cites this paper
• A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician’s perspective

  2018cites this paper
• A Rare Case of Triple-Negative Essential Thrombocythemia in a Young Postsplenectomy Patient: A Diagnostic Challenge

  2018cites this paper
• Prinzmetal Angina in a Young Patient with Essential Thrombocythemia, After Anagrelide Initiation - Case Report and Literature Review

  2018cites this paper
• Polycythemia vera and essential thrombocythemia

  2018cites this paper
• Myeloproliferative neoplasms (MPNs) - Part 1: An overview of the diagnosis and treatment of the "classical" MPNs.

  2018cites this paper
• Effects of polymorphic DNA genes involved in BER and caspase pathways on the clinical outcome of myeloproliferative neoplasms under treatment with hydroxyurea.

  2018cites this paper
• 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk‐Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

  2018cites this paper
• The effectiveness of exercise‐based rehabilitation to patients with myeloproliferative neoplasms—An explorative study

  2018cites this paper
• Cardiac Surgery Using Hypothermic Circulatory Arrest in a Case of Essential Thrombocythemia

  2018cites this paper
• New molecular and cellular aspects of mutant calreticulin in myeloproliferative neoplasms

  2018influential citation
• Assessment of Endothelial Dysfunction With Flow-Mediated Dilatation in Myeloproliferative Disorders

  2018cites this paper
• Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms

  2018cites this paper
• Néoplasies myéloprolifératives – Partie 1 : survol du diagnostic et du traitement des NMP « classiques »

  2018cites this paper
• The application of predictive statistical modelling in the investigation of suspected classical Myeloproliferative Neoplasms

  2018influential citation
• Genetic susceptibility to myeloproliferative neoplasms and therapeutic efficacy

  2018cites this paper
• Beyond JAK-2: potential targets for myeloproliferative neoplasm therapy

  2018cites this paper
• Myelodysplastic syndrome with fibrosis and complex karyotype arising in a patient with essential thrombocythaemia.

  2018cites this paper
• The Relationship Between the JAK 2V 617 F Mutation Status and Predictors of Clinical Outcomes in Patients with Essential Thrombocythemia

  2018cites this paper
• Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib

  2017cites this paper
• Myeloproliferative Neoplasms

  2017cites this paper
• Acute megakaryoblastic transformation from essential thrombocythemia

  2017cites this paper
• How We Treat Patients With Polycythemia Vera

  2017influential citation
• Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era

  2017cites this paper
• The Symptom Management of Myeloproliferative Neoplasms

  2017cites this paper
• Thrombocytosis and Essential Thrombocythaemia

  2017cites this paper
• The Symptom Management of Myeloproliferative Neoplasms

  2017cites this paper
• Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms

  2017cites this paper
• Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)

  2017influential citation
• Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV): results of a phase 2 study after a 7-year median follow-up

  2017cites this paper
• The Role of JAK2 in Myeloproliferative Neoplasms

  2017cites this paper
• Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery

  2017cites this paper
• Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study.

  2017cites this paper
• Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

  2017cites this paper
• DNA repair genes polymorphisms and genetic susceptibility to Philadelphia-negative myeloproliferative neoplasms in a Portuguese population: The role of base excision repair genes polymorphisms

  2017cites this paper
• Investigation of T-cell immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) polymorphisms in essential thrombocythaemia (ET)

  2017cites this paper
• JSH guideline for tumors of hematopoietic and lymphoid tissues—lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN)

  2017cites this paper
• Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera

  2017cites this paper
• CANCER-ASSOCIATED THROMBOTIC DISEASE Myeloproliferative neoplasms and thrombosis

  2017cites this paper
• Pronostic et prise en charge des grossesses chez les patientes porteuses d’une néoplasie myeloproliférative philadelphia-négative

  2017influential citation
• Gender and survival in essential thrombocythemia: A two‐center study of 1,494 patients

  2017influential citation
• Efficacy and safety of pegylated interferon alpha-2 a in patients with essential thrombocythemia ( ET ) and polycythemia vera ( PV ) : results of a phase 2 study after a 7-year median follow-up

  2017cites this paper
• After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.

  2017cites this paper
• Polycythemia and Thrombocytosis.

  2016cites this paper